147) A response to the problem receiving increasi |
148) witnessing a revival of its origins as a response to the rise of multi-drug resista |
149) hanisms of complex and rare diseases, the response to therapeutic treatments, and th |
150) s to modify cancer risk, progression, and response to therapy. |
151) wel disease (IBD) patients, including the response to therapy. |
152) bgroups, and to identify early markers of response to therapy. |
153) 4-RET fusion), to study RET signaling and response to therapy. |
154) our analysis, Theories of Change arose in response to three main problems: 1) the ne |
155) l functions such as process motility, the response to tissue injury, and the dynamic |
156) ought to develop as a coping mechanism in response to trauma exposure. |
157) adults, the unique pediatric physiologic response to trauma must be taken into cons |
158) ls would also be useful in evaluating the response to treatment in the pre-RA period |
159) rrent aphthous stomatitis, the course and response to treatment of squamous cell car |
160) infections; and prognosis of illness and response to treatment. |
161) ctivity differentiation and prediction of response to treatment. |
162) w RET+ models to elucidate differences in response to tyrosine kinase inhibitors and |
163) In response to unprecedented surges in the de |
164) widely from known FGF21 tissue sources in response to various stimuli. |
165) ally suppress the host NLRP3 inflammasome response to viral RNA while potentially in |
166) ual contributes to the susceptibility and response to viral infection. |
167) s, health behaviors, and mental health in response to weight loss (1-year) and weigh |
168) m by undergoing conformational changes in response to β-adrenergic stimulation that |
169) f the nucleolar proteome in TNBC cells in response to β-catenin inhibition. |
170) ll death pathway in bacteria occurring in response to β-lactam antibiotics. |
171) xious stimulation on direct MSA discharge/response. |
172) s for TNBC diagnosis, prognosis, and drug-response. |
173) plicing (a marker of the unfolded protein response). |
174) 68.5%, p = 0.0045), correlated with response. |
175) rature (Tcore) due to a decrease in sweat response. |
176) any organs and cause a broad pathological response. |
177) hown to have a major part in the HPA axis response. |
178) or affecting the enzyme activity and drug response. |
179) ontributing fundamentally to the COVID-19 response. |
|